Freeline Therapeutics
VerifiedBiopharmaceutical focused on the development and commercialisation of gene therapies for bleeding and other debilitating disorders.
Launch date
Employees
Market cap
$28.5m
Net debt
$25.5m
Enterprise valuation
$3m (Public information from Feb 2024)
Share price
$6.48 FRLN
Company register number 09500073
Stevenage England (HQ)